Shafique M, et al. - Among 30 patients with metastatic triple-negative breast cancer (TNBC) enrolled in this phase II trial, researchers tested selinexor (KPT-330, an oral selective inhibitor of nuclear export) with respect to its safety, pharmacodynamics, and effectiveness in these patients. They administered selinexor at 60 mg orally twice weekly on days 1 and 3 of each week, three of each 4-week cycle. They defined clinical benefit rate (CBR) as complete response + partial response + stable disease ≥12 weeks and considered it a primary objective. Fairly good tolerability of selinexor was evident in patients with advanced TNBC. However, selinexor did not result in objective responses. The observed CBR was 30%, so additional research in these patients should be focused on using selinexor in combination.